Clinical Trials

45 enrolled

Metastatic Gastric Adenocarcinoma

NCT05854498 2026-04-02

Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

NCT05806931 2026-03-18

SCOTI

Colonic Neoplasms, Rectal Neoplasms

NCT05343013 2026-03-06

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

25 enrolled

Colorectal Neoplasms

NCT04511039 2026-03-02

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer

Phase 1 Recruiting

45 enrolled

Colorectal Neoplasms

NCT07146646 2026-02-19

Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer

27 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07270991 2026-02-05

FRUQUITAS

Phase 3 Recruiting

324 enrolled

Tumor-Agnostic

Neoplasms

NCT06856837 2025-12-12

- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases

140 enrolled

Colorectal Neoplasms

NCT06245356 2025-12-10

TRIFLUOX-DP

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT07212933 2025-10-08

RAK in GC

90 enrolled

Stomach Neoplasms

NCT06887218 2025-08-27

5-Fluorouracil/Leucovorin (5FU/LV) in Combination With Regorafenib in Patients With Metastatic Colorectal Cancer

57 enrolled

Colorectal Neoplasms

NCT07085169 2025-07-25

Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC

Colonic Neoplasms

NCT07012954 2025-06-24

ctDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

64 enrolled

Colorectal Cancer Metastatic

NCT05965531 2025-04-29

TASLARC

65 enrolled

Rectal Neoplasms

NCT06711471 2024-12-02

Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer

31 enrolled

Gastric Cancer Adenocarcinoma Metastatic

NCT05476796 2024-10-24

LOGICAN

118 enrolled

Adenocarcinoma Of Esophagus, Adenocarcinoma, Neoplasm Metastasis, Recurrence

NCT06485713 2024-07-03

Efficacy and Safety of Trifluridine/Tipiracil Combined With Fufuquitinib for Third-line Treatment of mCRC

200 enrolled

Colorectal Neoplasms

NCT06379399 2024-04-23

Trifluridine/Tipiracil Combined With Cetuximab in the Treatment of Third-line and Above RAS/BRAF Wild-type mCRC

26 enrolled

Colorectal Cancer Metastatic

NCT06202001 2024-04-02

Irinotecan, TAS-102 Plus Bevacizumab as a Second-Line Therapy in mCRC Patients

70 enrolled

Colorectal Neoplasms

NCT04660760 2024-04-01

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

116 enrolled

Clinical Stage III Gastric Cancer AJCC v8

NCT05007132 2024-02-15

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

153 enrolled

Colorectal Neoplasms

NCT06242067 2024-02-05

BEV-TASIRI

Colorectal Neoplasms

NCT06102785 2023-10-26

Fruquintinib Combined With TAS102 for Advanced Gastric Cancer

Recruiting

30 enrolled

Stomach Neoplasms

NCT05970705 2023-08-01

Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC

101 enrolled